Eisai (ESAIY) and Biogen (BIIB) announced that the FDA has accepted Eisai’s Biologics License Application, BLA, for ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi ...

Older studies estimated a lower risk of dementia. According to new research, the number of people living with the disease in ...

Leading psychiatric educators are asking important questions about the best ways to train psychiatrists to address the needs ...

Nearly one in two Americans will develop dementia in their lifetimes, according to New York University researchers who say ...

New research finds that the lifetime risk of dementia after age 55 in Americans is 42%, significantly higher than previous ...

New research suggests that the risk for developing dementia is significantly higher than previously estimated, and the burden on the United States population will grow substantially over the next few ...

Cases of dementia in the United States are expected to rise to 1 million per year by 2060, with Black individuals, women and ...

Dear ProMIS Shareholders, In my first year as the Chief Executive Officer of ProMIS, we made great strides advancing our mission-driven innovation focused on developing precision-targeted therapies ...

Researchers at New York’s Mount Sinai Hospital have developed a cutting-edge AI-powered algorithm which could aid in the ...

They watched as dementia stole their parents’ memories, strength and finally their independence. Three daughters share the ...

A new study shows that the risk of developing dementia anytime after age 55 among Americans is 42%, more than double the risk reported by older studies.